Patients who are unable to reliably tolerate and/or receive oral medications
Inability to take oral medications on a continuous basis
Any condition that severely impairs patients ability to swallow whole pills
Ability to complete questionnaire(s) by themselves or with assistance
Ability to complete questionnaire(s) by themselves or with assistance
Participants must be able to take oral medications
Inability to swallow oral medications
Inability to swallow oral medication or to maintain a fast as required for 2 hours before and 1 hour after MLN8237 administration or any condition that would modify small bowel absorption of oral medications, including malabsorption, or resection of pancreas or upper bowel
Ability to complete questionnaire(s) by themselves or with assistance
Ability to swallow liquids
Subjects with severe claustrophobia unresponsive to oral anxiolytics
Ability to swallow oral medications
Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel* Active peptic ulcer disease* Malabsorption syndrome
Patients must be able to swallow oral medications
Ability to take oral medications
Ability to swallow oral medications
Within 90 days prior to registration: Complete dental exam; complete elimination of dental and periodontal pathology including crowns on teeth susceptible to fracture, extraction of non-restorable or periodontally uncorrectable teeth; creation of an oral environment that the patient can efficiently maintain in a high state of health; and oral hygiene instruction to maintain excellent oral health
Pre-existing conditions* Disorders associated with abnormal bone metabolism* Hypocalcemia that is not corrected with oral calcium supplementation* Vitamin D < 20 mg/mL* Pagets disease* Prior history or current evidence of osteonecrosis of the jaw* Any dental or oral condition likely to result in disruption of mucosal integrity during denosumab therapy including: active dental or jaw condition requiring oral surgery or tooth extraction; non-healed dental or oral surgery or planned invasive dental procedures during the anticipated course of study therapy* Unstable systemic disease, excluding osteosarcoma, such as unstable proximal renal tubule dysfunction (Fanconi syndrome) or congestive heart failure
Ability to swallow oral medications
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must have the ability to swallow oral dosage forms
Patients must be able to take oral medications (i.e., swallow pills whole); patients must not have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures that could in the opinion of the treating investigator affect absorption, or active peptic ulcer disease; patients with intractable nausea or vomiting are not eligible
Ability to swallow oral medications
No chronic (duration > 30 days) daily use of oral steroids
Patients required to be on any of the concomitant medications are excluded
Patients must not be taking oral glucocorticoids at the time of registration
Patients must be able to swallow oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients that unable to swallow oral medications are ineligible